Allogeneic CAR-T Therapy Market
完整報告名稱與涵蓋範圍
Allogeneic CAR-T Therapy Market Size, Share & Trends Analysis Report, By Cell Source (Healthy Donor T Cells, iPSC-Derived T and NK Cells, Cord Blood and Other Sources), By Gene Editing Technology (CRISPR-Based Editing, TALEN and Other Nuclease Platforms, Base Editing and Non-Nuclease Approaches), By Indication (B-Cell Lymphomas and Leukemias, Multiple Myeloma, Autoimmune Diseases, Solid Tumors), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The allogeneic CAR-T therapy market covers off-the-shelf chimeric antigen receptor T-cell and closely related NK-cell products manufactured from healthy donor cells, induced pluripotent stem cells or other non-patient sources, including the gene-editing and manufacturing platforms that enable them. Autologous CAR-T products and in vivo CAR-T approaches are excluded, though their pricing and treatment-pathway dynamics are analysed as competitive references.
The commercial case rests on removing patient-specific manufacturing: donor-derived batches can be produced in advance, inventoried and released within days, at a fraction of the cost of autologous products, which is critical for reaching community hospitals and for autoimmune indications where autologous economics are difficult to justify. Progress has been uneven, with persistence, host rejection and graft-versus-host risk requiring multiplex editing, alloimmune-evasion designs and optimised lymphodepletion. Pivotal programs in large B-cell lymphoma and autoimmune disease, together with iPSC-derived candidates entering later-stage trials, define the approval timeline modelled in the study.
The United States leads development and holds most trial sites, with Europe, China and Japan contributing platform companies and manufacturing capacity. Competition involves specialist allogeneic developers, gene-editing companies and large pharmaceutical groups that have partnered or acquired their way into the field.
The InsightAce study supplies US$ forecasts for all cell source, gene editing technology, indication and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Allogeneic CAR-T Therapy Market Snapshot
Chapter 4. Global Allogeneic CAR-T Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Cell Source Estimates & Trend Analysis
5.1. Cell Source & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Cell Source:
5.2.1. Healthy Donor T Cells
5.2.2. iPSC-Derived T and NK Cells
5.2.3. Cord Blood and Other Sources
Chapter 6. Market Segmentation 2: By Gene Editing Technology Estimates & Trend Analysis
6.1. Gene Editing Technology & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Gene Editing Technology:
6.2.1. CRISPR-Based Editing
6.2.2. TALEN and Other Nuclease Platforms
6.2.3. Base Editing and Non-Nuclease Approaches
Chapter 7. Market Segmentation 3: By Indication Estimates & Trend Analysis
7.1. Indication & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
7.2.1. B-Cell Lymphomas and Leukemias
7.2.2. Multiple Myeloma
7.2.3. Autoimmune Diseases
7.2.4. Solid Tumors
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Hospitals and Cell Therapy Centers
8.2.2. Outpatient Infusion Centers
Chapter 9. Allogeneic CAR-T Therapy Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Allogene Therapeutics, Inc.
11.2. CRISPR Therapeutics AG
11.3. Caribou Biosciences, Inc.
11.4. Cellectis S.A.
11.5. Precision BioSciences, Inc.
11.6. Fate Therapeutics, Inc.
11.7. Sana Biotechnology, Inc.
11.8. Poseida Therapeutics (Roche)
11.9. Century Therapeutics, Inc.
11.10. Atara Biotherapeutics, Inc.
11.11. Nkarta, Inc.
11.12. Takeda Pharmaceutical Company Limited
11.13. Servier
11.14. AstraZeneca plc (Gracell Biotechnologies)
11.15. Bioheng Therapeutics
圖表清單 List of Tables & Figures
Table 1. Global Allogeneic CAR-T Therapy Revenue Forecast by Cell Source, 2026-2035 (US$ Mn)
Figure 1. Global Allogeneic CAR-T Therapy Market Snapshot, 2026 & 2035
Table 2. Global Allogeneic CAR-T Therapy Revenue Forecast by Gene Editing Technology, 2026-2035 (US$ Mn)
Figure 2. Global Allogeneic CAR-T Therapy Market Share by Gene Editing Technology, 2026 & 2035
Table 3. Global Allogeneic CAR-T Therapy Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 3. Allogeneic CAR-T Pipeline by Cell Source, Editing Platform and Phase
Table 4. Global Allogeneic CAR-T Therapy Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Cost of Goods and Vein-to-Vein Time: Allogeneic Versus Autologous CAR-T
Table 5. North America Allogeneic CAR-T Therapy Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Allogeneic CAR-T Therapy Growth Opportunity Analysis
Table 6. Europe Allogeneic CAR-T Therapy Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Alloimmune Evasion and Persistence Strategies in Clinical Development
Table 7. Asia Pacific Allogeneic CAR-T Therapy Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Allogeneic CAR-T Therapy Market Participants
Table 8. Latin America and Middle East & Africa Allogeneic CAR-T Therapy Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們